<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898154</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0533</org_study_id>
    <nct_id>NCT03898154</nct_id>
  </id_info>
  <brief_title>Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures</brief_title>
  <official_title>The Effect on Wrist Range of Motion With Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. Liam Dwyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to compare functional outcome measures and range of
      motion for patients receiving glucocorticoid (GC) injections versus those not receiving GCs
      for the treatment of distal radius fractures. The investigators hypothesize that patients who
      receive GC will have improved ROM and functional outcome measures compared to patients who do
      not receive GC. In addition, this study aims to determine if there is a difference in rates
      of complications and postoperative pain control between the GC and non-GC groups. In order to
      accomplish these aims, the investigators will conduct a prospective, randomized, controlled
      investigation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QuickDASH</measure>
    <time_frame>0-12 months</time_frame>
    <description>best 0-100 worst; functional outcome score for disabilities of the arm, shoulder, and hand</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale Pain Score</measure>
    <time_frame>0-12 months</time_frame>
    <description>best 0-10 worst; continuous scale to measure current pain level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PROMIS Pain Interference</measure>
    <time_frame>0-12 months</time_frame>
    <description>best 0-100 worst; measures the effects of a patient's pain on their daily activities and lifestyle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PROMIS Self-Efficacy Manage Symptoms</measure>
    <time_frame>0-12 months</time_frame>
    <description>best 0-100 worst; measures a patient's ability to cope with their symptoms related to the procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PROMIS Upper Extremity</measure>
    <time_frame>0-12 months</time_frame>
    <description>worst 0-100 best; measures physical function of upper extremities</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Distal Radius Fracture</condition>
  <arm_group>
    <arm_group_label>Glucocorticoid (GC) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (non-GC) group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No GC administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone</description>
    <arm_group_label>Glucocorticoid (GC) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6</description>
    <arm_group_label>Glucocorticoid (GC) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years of age and older.

          -  Patients undergoing ORIF with VP fixation of an acute, isolated DRF with or without
             associated distal ulna fracture and with or without associated carpal tunnel release

        Exclusion Criteria:

          -  Worker's compensation patient

          -  Non-operatively treated fractures

          -  Open fractures

          -  Preoperative neurovascular injury

          -  Coexisting fractures or injuries

          -  Diabetes mellitus

          -  Allergy or contraindication to GCs

          -  Associated non-orthopedic injury that would prohibit the administration of GCs

          -  Patients currently incarcerated

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liam Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liam Dwyer, MD</last_name>
    <phone>570-214-4806</phone>
    <email>orthoresearch@geisinger.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geisinger Woodbine</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Harding, MPA</last_name>
      <phone>570-214-6178</phone>
      <email>jlharding1@geisinger.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Geisinger Clinic</investigator_affiliation>
    <investigator_full_name>C. Liam Dwyer</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Radius Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

